Different protective and reparative effects of olmesartan in stroke according to time of administration and withdrawal

Gutiérrez-Fernández, María; Fuentes, Blanca; Rodríguez-Frutos, Berta; Ramos‐Cejudo, Jaime; Otero-Ortega, Laura; Díez‐Tejedor, Exuperio

doi:10.1002/jnr.23532

Cited by 7 publications

(2 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Arterial hypertension, and related target organ damaging, is generally accompanied by a chronic inflammatory response[63], and several inflammatory molecules are thought to modulate cellular functions, including oxido-reductive balance. Plasma levels of CRP and fibrinogen were lowered after treatment, confirming the already reported anti-inflammatory effect of olmesartan[50,64]. …”

Section: Discussionsupporting

confidence: 82%

Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effects

et al. 2017

View full text Add to dashboard Cite

CD34+ circulating progenitor cells (CD34+CPCs) are a population of multipotent cells which can delay the development of atherosclerosis and cardiovascular disease (CVD) in conditions of increased CV risk. MicroRNAs (miRs) 221 and 222 modulate different genes regulating angiogenesis and inflammation; moreover, miR221/22 have beenshown to participate in differentiation and proliferation of CD34+CPCs, inhibiting cell migration and homing. miR221/222 in CD34+CPCs from hypertensive subjects are also increased and associated with CD34+cell number and reactive oxygen species (ROS). We evaluated CD34+CPC number, intracellular miR221/222 and ROS levels, arterial stiffness (AS)and echocardiography indices at baseline (T0).Then, after a six-month treatment with olmesartan, 20 mg/day (T1), in 57 hypertensive patients with left ventricular hypertrophy (LVH) and with no additional risk factor for CVD, and in 29 healthy controls (baseline),fibrinogen, C-reactive protein (CRP), glucose and lipid profiles were also evaluated.At T1, blood pressure values, CRP and fibrinogen levels, ROS and miR221/222 were significantly decreased (all p <0.001), as were AS indices and LV mass index (p<0.001), while cell number was increased (p<0.001). Olmesartan is effective in reducing miR and ROS levels in CD34+CPCs from hypertensive subjects, as well as in increasing CD34+CPC number, providing multilevel CV protection, in addition to its expected pharmacological effects.

show abstract

Section: Discussionsupporting

confidence: 82%

Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effects

et al. 2017

View full text Add to dashboard Cite

show abstract

“…A single carotid ligation stroke model in gerbils showed that OMS (10 mg/kg per day started 36 h after stroke) was associated with an increased survival [74]. Other studies demonstrated that OMS (10 mg/kg per day for 14 days after infarct; 10 mg/kg per day for 7 days before and 14 days after infarct; 10 mg/kg per day for 7 days before infarct) treatment in a rat MCAO model showed significantly better functional scores and reduced infarct size and cell death [75]. OMS (0.01 or 0.1 µmol/kg per hour for seven days) reduced brain angiotensin II, MMP-2 and MMP-9 upregulation following brain ischemia [77].…”

Section: Drugmentioning

confidence: 96%

The Role of Sartans in the Treatment of Stroke and Subarachnoid Hemorrhage: A Narrative Review of Preclinical and Clinical Studies

et al. 2020

View full text Add to dashboard Cite

Background: Delayed cerebral vasospasm (DCVS) due to aneurysmal subarachnoid hemorrhage (aSAH) and its sequela, delayed cerebral ischemia (DCI), are associated with poor functional outcome. Endothelin-1 (ET-1) is known to play a major role in mediating cerebral vasoconstriction. Angiotensin-II-type-1-receptor antagonists such as Sartans may have a beneficial effect after aSAH by reducing DCVS due to crosstalk with the endothelin system. In this review, we discuss the role of Sartans in the treatment of stroke and their potential impact in aSAH. Methods:We conducted a literature research of the MEDLINE PubMed database in accordance with PRISMA criteria on articles published between 1980 to 2019 reviewing: "Sartans AND ischemic stroke". Of 227 studies, 64 preclinical and 19 clinical trials fulfilled the eligibility criteria. Results: There was a positive effect of Sartans on ischemic stroke in both preclinical and clinical settings (attenuating ischemic brain damage, reducing cerebral inflammation and infarct size, increasing cerebral blood flow). In addition, Sartans reduced DCVS after aSAH in animal models by diminishing the effect of ET-1 mediated vasoconstriction (including cerebral inflammation and cerebral epileptogenic activity reduction, cerebral blood flow autoregulation restoration as well as pressure-dependent cerebral vasoconstriction). Conclusion: Thus, Sartans might play a key role in the treatment of patients with aSAH.Multiple studies showed that endothelin-1 (ET-1), a most potent vasoconstrictor [9][10][11], plays a key role in the development of DCVS [12][13][14][15][16][17][18][19]. Although endothelin-A-receptor (ET A -R) antagonists in the treatment of DCVS in animal models are effective [10,20], clinical studies did not show beneficial effects [21,22]. It has been reported that the polypeptide angiotensin-II acts through two specific receptors, in essence the angiotensin-II-type-1-and angiotensin-II-type-2-receptor (AT 2 -1-R and AT 2 -2-R). Important to note is that activation of the AT 2 -1-R results in vasoconstriction while binding of angiotensin-II to the AT 2 -2-R causes vasorelaxation [23]. In line with this notion, preclinical as well as clinical trials showed promising results of Sartans, which are AT 2 -1-R antagonists, in ischemic stroke. Hence, Sartans may have a positive effect after aSAH by reducing DCVS due to crosstalk with the endothelin system. Thus, we aimed to analyze the potential role of Sartans in the treatment of aSAH. Materials and MethodsWe conducted a systematic literature research of the MEDLINE PubMed database in accordance with PRISMA guidelines on preclinical studies on the one and on clinical studies on the other hand published between 1980 to 2019 reviewing: "Sartans and ischemic stroke" [24]. Only articles in English were chosen for review. Search items with "Sartans" (n = 19,064) and "ischemic stroke" (n = 89,465) were extracted. For "Sartans AND ischemic stroke", 227 publications met the inclusion criteria by excluding studies with commentary only, any dupli...

show abstract

Drug Evaluation: Olmesartan Medoxomil + Rosuvastatin for the Treatment of Dyslipidemia and Concomitant Risk Factors: A Chance for Better Compliance?

Gozdzikiewicz-Lapinska¹,

Małyszko²

2015

Combination Therapy in Dyslipidemia

View full text Add to dashboard Cite

Different protective and reparative effects of olmesartan in stroke according to time of administration and withdrawal

Cited by 7 publications

References 44 publications

Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effects

Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effects

The Role of Sartans in the Treatment of Stroke and Subarachnoid Hemorrhage: A Narrative Review of Preclinical and Clinical Studies

Drug Evaluation: Olmesartan Medoxomil + Rosuvastatin for the Treatment of Dyslipidemia and Concomitant Risk Factors: A Chance for Better Compliance?

Contact Info

Product

Resources

About